Lova Sun

3.6k total citations
86 papers, 1.9k citations indexed

About

Lova Sun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Lova Sun has authored 86 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 19 papers in Otorhinolaryngology. Recurrent topics in Lova Sun's work include Lung Cancer Treatments and Mutations (31 papers), Head and Neck Cancer Studies (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Lova Sun is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Head and Neck Cancer Studies (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Lova Sun collaborates with scholars based in United States, United Kingdom and Canada. Lova Sun's co-authors include Ramanan Laxminarayan, Eili Klein, Daria V. Babushok, Gary D. Kao, Daniel Y. Joh, Jay F. Dorsey, Andrew Tsourkas, David L. Smith, Shree R. Singh and Shreekumar Pillai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lova Sun

70 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lova Sun United States	20	441	435	308	302	292	86	1.9k
June M. McKoy United States	22	278 0.6×	290 0.7×	494 1.6×	451 1.5×	63 0.2×	47	2.2k
Richard D. Mamelok United States	30	251 0.6×	130 0.3×	846 2.7×	114 0.4×	283 1.0×	55	3.6k
Oyedele Adeyi Canada	27	187 0.4×	521 1.2×	367 1.2×	56 0.2×	415 1.4×	96	3.7k
Edward L.G. Pryzdial Canada	24	262 0.6×	472 1.1×	84 0.3×	656 2.2×	93 0.3×	60	1.9k
Patricia Campbell Canada	30	290 0.7×	784 1.8×	144 0.5×	107 0.4×	111 0.4×	89	3.4k
Don A. Gabriel United States	28	633 1.4×	141 0.3×	173 0.6×	888 2.9×	112 0.4×	100	2.2k
Steven R. Deitcher United States	32	366 0.8×	102 0.2×	366 1.2×	1.0k 3.4×	238 0.8×	107	3.8k
Daisuke Kudo Japan	28	313 0.7×	375 0.9×	409 1.3×	114 0.4×	86 0.3×	168	2.4k
Charles Du Mond United States	11	240 0.5×	80 0.2×	470 1.5×	145 0.5×	205 0.7×	15	1.4k
Xiaohong Jiang China	20	226 0.5×	168 0.4×	218 0.7×	333 1.1×	124 0.4×	69	1.5k

Countries citing papers authored by Lova Sun

Since Specialization

Citations

This map shows the geographic impact of Lova Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lova Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lova Sun more than expected).

Fields of papers citing papers by Lova Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lova Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lova Sun. The network helps show where Lova Sun may publish in the future.

Co-authorship network of co-authors of Lova Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Lova Sun. A scholar is included among the top collaborators of Lova Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lova Sun. Lova Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Lova, Roger B. Cohen, & A. Dimitrios Colevas. (2024). Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Oral Oncology. 158. 106997–106997. 4 indexed citations

Hanna, Glenn J., James Jabalee, John N. Lukens, et al.. (2024). Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer. Oral Oncology. 158. 107002–107002. 3 indexed citations

Patel, Aman M., Jason A. Brant, Karthik Rajasekaran, et al.. (2024). Primary site surgical resection in cM1 oral cavity squamous cell carcinoma. Laryngoscope Investigative Otolaryngology. 9(5). e70000–e70000. 5 indexed citations

Reibel, Jacob B., Lova Sun, Ravi B. Parikh, et al.. (2024). Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. JNCI Journal of the National Cancer Institute. 117(6). 1276–1278.

Sun, Lova, Jérôme Fayette, Sébastien Salas, et al.. (2024). Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C.. Journal of Clinical Oncology. 42(16_suppl). 6012–6012. 7 indexed citations

Lukens, John N., Emily MacDuffie, G S Weinstein, et al.. (2024). Phase II Study of Radiation Volume and Dose De-Intensification Following Tors and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma – Long-Term Results of Expanded Cohort. International Journal of Radiation Oncology*Biology*Physics. 120(2). S121–S121.

Sun, Lova, Joshua E. Reuss, Geoffrey Liu, et al.. (2023). P2.31-05 Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data. Journal of Thoracic Oncology. 18(11). S408–S409.

Aggarwal, Charu, Melina E. Marmarelis, Wei‐Ting Hwang, et al.. (2023). Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. JCO Precision Oncology. 7(7). e2300191–e2300191. 22 indexed citations

Lee, Sang Ho, Bolin Li, Abigail Doucette, et al.. (2023). The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiotherapy and Oncology. 190. 110030–110030. 17 indexed citations

10.

Aggarwal, Charu, Joshua Bauml, Tomás S. Alemán, et al.. (2023). A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer. The Oncologist. 28(7). 644–e564. 13 indexed citations

11.

Lee, Sang Ho, Bolin Li, William P. Levin, et al.. (2023). Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors. International Journal of Radiation Oncology*Biology*Physics. 118(5). 1435–1444. 9 indexed citations

12.

Narayan, Vivek, Tao Liu, Xue Song, et al.. (2023). Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs. Journal of the National Comprehensive Cancer Network. 21(10). 1039–1049.e10. 2 indexed citations

13.

Sannigrahi, Malay K., Pavithra Rajagopalan, Lova Sun, et al.. (2023). A novel pipeline for prioritizing cancer type‐specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas. Molecular Oncology. 18(2). 336–349. 3 indexed citations

14.

Sun, Lova, Robert M. Brody, Julie A. Lynch, et al.. (2023). Risk of Cardiovascular Events Among Patients With Head and Neck Cancer. JAMA Otolaryngology–Head & Neck Surgery. 149(8). 717–717. 16 indexed citations

15.

Lee, Sang Ho, Lova Sun, Roger B. Cohen, et al.. (2023). Association of Cardiac Dose with Cardiac Events and Survival for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Concurrent Chemoradiotherapy (cCRT) in the Era of Immune Checkpoint Inhibitor (ICI) Consolidation. International Journal of Radiation Oncology*Biology*Physics. 117(2). S169–S170. 1 indexed citations

16.

Hahn, Virginia S., Kathleen W. Zhang, Lova Sun, et al.. (2021). Heart Failure With Targeted Cancer Therapies. Circulation Research. 128(10). 1576–1593. 46 indexed citations

17.

Thompson, Elizabeth, Biniyam G. Demissei, Amanda M. Smith, et al.. (2021). Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. JACC Basic to Translational Science. 7(1). 1–10. 7 indexed citations

18.

Sun, Lova, Anh N. Le, Abigail Doucette, et al.. (2020). Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum. 5(1). 27 indexed citations

19.

Sun, Lova, Christiana Davis, Wei‐Ting Hwang, et al.. (2020). Outcomes in Patients With Non–small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer. 22(1). 58–66.e3. 30 indexed citations

20.

Colling, Meaghan, Lova Sun, Vivek Upadhyay, et al.. (2020). Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion. 60(4). 841–846. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact